Bierman Steve F, Weil Andrew, Dahmer Stephen
College of Medicine, University of Arizona, Tucson, AZ, United States.
Front Psychiatry. 2024 Dec 6;15:1474558. doi: 10.3389/fpsyt.2024.1474558. eCollection 2024.
Thousands of essays and studies have been published on placebo and nocebo. Yet, despite this plethora of information, we are not much closer to a comprehensive understanding of the fundamental mechanism producing placebo and nocebo effects than we were in 1946, when participants in the Cornell Conferences on Therapy speculated on the roles of authority, belief and expectancy. In this paper, we examine the weaknesses in current placebo and nocebo definitions and theories. We also propose a more concise and comprehensive definition and theory of placebo and nocebo by introducing the Law of Identification and the Generic Placebo Instruction (GPI). The latter being the placebo/nocebo information expressed or implied in virtually every clinical encounter and trial; the former (i.e., the Law of Identification), being what drives the GPI to actualization. Further, we demonstrate the explanatory power of this new theory and suggest clinical studies that test predictions arising from it - studies whose results, if positive, would translate universally into clinical practice.
关于安慰剂和反安慰剂效应,已经发表了成千上万篇论文和研究报告。然而,尽管有如此丰富的信息,但与1946年康奈尔治疗会议上的参与者推测权威、信念和期望的作用时相比,我们距离全面理解产生安慰剂和反安慰剂效应的基本机制并没有更近多少。在本文中,我们审视了当前安慰剂和反安慰剂定义及理论中的弱点。我们还通过引入识别定律和通用安慰剂指令(GPI),提出了一个更简洁、更全面的安慰剂和反安慰剂定义及理论。后者是几乎在每一次临床诊疗和试验中表达或暗示的安慰剂/反安慰剂信息;前者(即识别定律)则是驱使GPI得以实现的因素。此外,我们展示了这一新理论的解释力,并建议开展临床研究来检验由此产生的预测——这些研究的结果如果是积极的,将普遍转化为临床实践。